Close Menu

NEW YORK (GenomeWeb) – Despite setbacks in recent years, diagnostics firm Epigenomics continues to push for clinical adoption and reimbursement of its colorectal cancer screening test Epi proColon, hoping to cement its position in the blood-based detection market at a time when a number of new companies have begun to stake claims but few have yet proved their technologies in the clinic.

Among recent milestones, the firm has launched a kit version of the epigenomic test technology behind Epi proColon, announcing the product last month.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.